PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.
The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.
Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.
Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.
Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Taking part in creative activities and enjoying arts and culture may not only improve mental well-being but could also help people age more slowly, according to a new study from University College London (UCL) in the UK. For the study, published in the journal Innovation in Aging, researchers studied...
After more than 10 years of discussions with experts and patients around the world, PCOS (polycystic ovary syndrome) has been renamed PMOS (polycystic endocrine metabolic ovarian syndrome) by a global science group. The new name was announced at the European Congress of Endocrinology in Prague after...
The U.S. Food and Drug Administration on Tuesday took two decisive actions focused on food chemical safety. First, the agency finalized its new proactive food chemical safety post-market assessment program. Second, the FDA launched reassessments of butylated hydroxytoluene (BHT) and azodicarbonamide...
A new 36-month update from UroGen Pharma's (URGN) pivotal Phase 3 ENVISION trial showed that many patients who achieved an early complete response with ZUSDURI (mitomycin) remained disease-free through three years, reinforcing the therapy's durability in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).